Document is current

Article History

Received: 7 November 2022

Accepted: 14 February 2023

First Online: 6 March 2023

Competing interests

: The authors declare the following competing interests: Stephen A. Johnson – reports research support from the ALS Association. Marta Karas – reports no competing interests. Katherine M. Burke – reports no competing interests. Marcin Straczkiewicz – reports no competing interests. Zoe A. Scheier – reports no competing interests. Alison P. Clark – reports no competing interests. Satoshi Iwasaki – employee of Mitsubishi Tanabe Pharma Holdings America, Inc. Amir Lahav – paid strategic advisor for digital health at Mitsubishi Tanabe Pharma Holdings America, Inc. He has been paid for consulting services for Redenlab, Curebase, Castor, Lapsi Health, Solo AI, Quantificare, and the Global Platform Alzheimer’s Foundation. He has an unpaid role on the advisory board for the non-profit Everything ALS. Amrita S. Iyer – reports no competing interests. Jukka-Pekka Onnela – reports no competing interests. James D. Berry – reports research support from Biogen, MT Pharma Holdings of America, Transposon Therapeutics, Alexion, Rapa Therapeutics, ALS Association, Muscular Dystrophy Association, ALS One, Tambourine, ALS Finding a Cure. He has been a paid member of an advisory panel for Regeneron, Biogen, Clene Nanomedicine, Mitsubishi Tanabe Pharma Holdings America, Inc., Janssen, RRT. He received an honorarium for educational events for Projects in Knowledge and the Muscular Dystrophy Association. He has unpaid roles on the advisory boards for the non-profits Everything ALS and ALS One. Mitsubishi Tanabe Pharma Holdings America, Inc. (MTPHA) was a sponsor of this study. MTPHA has not restricted in any way publication of the full data set nor the authors’ right to publish. The academic authors retained full editorial control throughout manuscript preparation.